-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TextPharmaceutical Guanlan
On January 10, Ascletis announced that the company has submitted a clinical trial application (IND) in the United States for its fully self-developed oral PD-L1 small molecule inhibitor ASC61 for the treatment of advanced solid tumors
.
According to Ascletis in a press release, ASC61 is a potent and highly selective oral PD-L1 small-molecule inhibitor developed by the company.
It can induce the formation and internalization of PD-L1 dimer phagocytosis, thereby blocking the PD-1/PD-L1 interaction
.
In a variety of animal models such as humanized mouse models, ASC61 single drug has shown significant anti-tumor efficacy
According to the press release, the oral PD-L1 inhibitor ASC61 has the following advantages over anti-PD-1/PD-L1 antibody injections:
It is convenient to administer, and there is no need to go to the hospital for injections; it can be combined with other oral antitumor drugs to form an all-oral treatment plan; the dosage can be adjusted in time to better manage immune-related adverse events
(Original abridged)
